Read about a single antibody approach aimed at protecting the blood-brain barrier and progressing toward clinical testing after fresh funding.
Key Takeaways
- Company raised over €25 million including a >€5 million Michael J
- New financing will fund regulatory studies, manufacturing, and Phase 1a/1b clinical trials
- LYS241 is an antibody designed to preserve the blood-brain barrier from within vessels